Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine

Transplantation

Volumn 67, Issue 1, 1999, Pages 145-151

  Troncoso, Pablo ^a   Stepkowski, Stanislaw M ^a   Wang, Mou Er ^a   Qu, Xumei ^a   Chueh, Shih Chieh ^a   Clark, James ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FINGOLIMOD; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL TRANSPLANTATION; FEMALE; GRAFT SURVIVAL; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT REJECTION; MIXED LYMPHOCYTE CULTURE; MONKEY; NONHUMAN; PRIORITY JOURNAL;

EID: 0033556558     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199901150-00024     Document Type: Article

References (24)

1. Adachi K, Kohara T, Nakano, et al. Design, synthesis, and structure-activity relationship of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem 1995; 5: 853.
2. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites: a potent immunosuppressive activity found in Isaria Sinclaririi metabolite. J Antibiot (Tokyo) 1994; 47: 208.
3. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996; 61: 200.
4. Chiba K, Hoshino Y, Suzuki C, et al. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc 1996; 28: 1056.
5. Hoshino Y, Suzuki C, Ohtsuki M, Masubuchi Y, Amano Y, Chiba K. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc 1996; 28: 1060.
6. Suzuki S, Ensenowa S, Kakefuda T, Amemiya H, Hoshino Y, Chiba K. Long-term graft acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY720. Transplant Proc 1996; 28: 1375.
7. Masubuchi Y, Kawaguchi T, Ohtsuki M, et al. FTY720, a novel immunosuppressant possessing unique mechanisms. IV. Prevention of graft versus host reactions in rats. Transplant Proc 1996; 28: 1064.
8. Wang M-E, Tejpal N, Qu X, et al. Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus. Transplantation 1998; 65: 899.
9. Suzuki S, Li X-K, Enosawa S, Shinomiya T. A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology 1996; 89: 518.
10. Li X-K, Shinomiya T, Enosawa S, Kakefuda T, Amemiya H, Suzuki S. Induction of lymphocyte apoptosis by a novel immunosuppressant, FTY720: relation with Fas, Bcl-2, and Bax expression. Transplant Proc 1997; 29: 1267.
11. Li X-K, Enosawa S, Kakefuda T, Amemiya H, Suzuki S. FTY720, a novel immunosuppressive agent, enhances upregulation of the cell adhesion molecule ICAM-1 in TNF-α-treated human umbilical vein endothelial cells. Transplant Proc 1997; 29: 1265.
12. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720: a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998; 160: 5037.
13. Kawaguchi T, Hoshino Y, Rahman F, et al. FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A. Transplant Proc 1996; 28: 1062.
14. Rideout DC, Chou T-C. Introduction. In: Chou T-C, Rideout DC, eds. Synergism, antagonism, and potentiation in chemotherapy. San Diego: Academic Press, 1991: 3.
15. Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998; 160: 5493.
16. Cosimi AB, Conti D, Delmonico FL, et al. In vivo effects of monoclonal antibody to intrercellular adhesion molecule-1 (CD54) in nonhuman primates with renal allografts. J Immunol 1990; 144: 4606.
17. Calne R, White DJ, Third S, et al. Cyclosporine A in patients receiving renal allografts from cadaver donors. Lancet 1987; 2: 1223.
18. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
19. Dunn J, Golden D, Van Buren CT, Lewis RM, Lawen J, Kahan BD. Causes of graft loss beyond two years in the cyclosporine era. Transplantation 1990; 49: 349.
20. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou T-C. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232.
21. Stepkowski SM, Napoli KL, Wang M-E, Qu X, Chou T-C, Kahan BD. The effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation 1996; 62: 986.
22. Tu Y, Stepkowski SM, Chou TC, Kahan BD. The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. Transplantation 1995; 59: 177.
23. Kahan BD. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 1997; 29: 48.
24. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisolone-treated renal transplant patients. Kidney Int 1996; 49: 209.